-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

Benzinga·11/05/2026 10:23:35
Listen to the news
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $18 to $20.